c-myc amplification in ovarian cancer

Vicki V. Baker, Matthew P. Borst, Diane Dixon, Kenneth D Hatch, Hugh M. Shingleton, Donald Miller

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

The c-myc oncogene codes for a DNA binding protein that appears to play an important role in the regulation of cell growth. c-myc gene amplification has been documented to occur in both hematopoietic and solid neoplasms and often indicates more biologically aggressive tumors. Southern hybridization analysis was performed on high-molecular-weight DNA isolated from primary ovarian carcinomas. Major structural rearrangements of c-myc were not detected. Five of seventeen (29.4%) tumor samples demonstrated amplification of the myc oncogene. The 5 patients with ovarian carcinomas associated with c-myc amplification exhibited a median survival of 17 months. Of the 12 patients without evidence of tumor-associated c-myc amplification, 5 have exhibited disease-free survival for an average of 36.8 months and are currently alive. The remaining 7 patients, the majority of whom had advanced-stage, poorly differentiated lesions with a normal c-myc copy number, exhibited a median survival of 9 months. There was no apparent relationship between c-myc amplification, grade of tumor differentiation, and response to platinol-based chemotherapy. These data do not suggest a prognostic role for c-myc amplification in primary ovarian cancer. However, c-myc amplification is a common finding in advanced-stage ovarian cancer.

Original languageEnglish (US)
Pages (from-to)340-342
Number of pages3
JournalGynecologic Oncology
Volume38
Issue number3
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Ovarian Neoplasms
myc Genes
Neoplasms
Carcinoma
Survival
Gene Amplification
DNA-Binding Proteins
Hematologic Neoplasms
Cisplatin
Disease-Free Survival
Molecular Weight
Drug Therapy
DNA
Growth

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Baker, V. V., Borst, M. P., Dixon, D., Hatch, K. D., Shingleton, H. M., & Miller, D. (1990). c-myc amplification in ovarian cancer. Gynecologic Oncology, 38(3), 340-342. https://doi.org/10.1016/0090-8258(90)90069-W

c-myc amplification in ovarian cancer. / Baker, Vicki V.; Borst, Matthew P.; Dixon, Diane; Hatch, Kenneth D; Shingleton, Hugh M.; Miller, Donald.

In: Gynecologic Oncology, Vol. 38, No. 3, 1990, p. 340-342.

Research output: Contribution to journalArticle

Baker, VV, Borst, MP, Dixon, D, Hatch, KD, Shingleton, HM & Miller, D 1990, 'c-myc amplification in ovarian cancer', Gynecologic Oncology, vol. 38, no. 3, pp. 340-342. https://doi.org/10.1016/0090-8258(90)90069-W
Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. c-myc amplification in ovarian cancer. Gynecologic Oncology. 1990;38(3):340-342. https://doi.org/10.1016/0090-8258(90)90069-W
Baker, Vicki V. ; Borst, Matthew P. ; Dixon, Diane ; Hatch, Kenneth D ; Shingleton, Hugh M. ; Miller, Donald. / c-myc amplification in ovarian cancer. In: Gynecologic Oncology. 1990 ; Vol. 38, No. 3. pp. 340-342.
@article{50814c79a5754a7a9ed6946b1ab68ee3,
title = "c-myc amplification in ovarian cancer",
abstract = "The c-myc oncogene codes for a DNA binding protein that appears to play an important role in the regulation of cell growth. c-myc gene amplification has been documented to occur in both hematopoietic and solid neoplasms and often indicates more biologically aggressive tumors. Southern hybridization analysis was performed on high-molecular-weight DNA isolated from primary ovarian carcinomas. Major structural rearrangements of c-myc were not detected. Five of seventeen (29.4{\%}) tumor samples demonstrated amplification of the myc oncogene. The 5 patients with ovarian carcinomas associated with c-myc amplification exhibited a median survival of 17 months. Of the 12 patients without evidence of tumor-associated c-myc amplification, 5 have exhibited disease-free survival for an average of 36.8 months and are currently alive. The remaining 7 patients, the majority of whom had advanced-stage, poorly differentiated lesions with a normal c-myc copy number, exhibited a median survival of 9 months. There was no apparent relationship between c-myc amplification, grade of tumor differentiation, and response to platinol-based chemotherapy. These data do not suggest a prognostic role for c-myc amplification in primary ovarian cancer. However, c-myc amplification is a common finding in advanced-stage ovarian cancer.",
author = "Baker, {Vicki V.} and Borst, {Matthew P.} and Diane Dixon and Hatch, {Kenneth D} and Shingleton, {Hugh M.} and Donald Miller",
year = "1990",
doi = "10.1016/0090-8258(90)90069-W",
language = "English (US)",
volume = "38",
pages = "340--342",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - c-myc amplification in ovarian cancer

AU - Baker, Vicki V.

AU - Borst, Matthew P.

AU - Dixon, Diane

AU - Hatch, Kenneth D

AU - Shingleton, Hugh M.

AU - Miller, Donald

PY - 1990

Y1 - 1990

N2 - The c-myc oncogene codes for a DNA binding protein that appears to play an important role in the regulation of cell growth. c-myc gene amplification has been documented to occur in both hematopoietic and solid neoplasms and often indicates more biologically aggressive tumors. Southern hybridization analysis was performed on high-molecular-weight DNA isolated from primary ovarian carcinomas. Major structural rearrangements of c-myc were not detected. Five of seventeen (29.4%) tumor samples demonstrated amplification of the myc oncogene. The 5 patients with ovarian carcinomas associated with c-myc amplification exhibited a median survival of 17 months. Of the 12 patients without evidence of tumor-associated c-myc amplification, 5 have exhibited disease-free survival for an average of 36.8 months and are currently alive. The remaining 7 patients, the majority of whom had advanced-stage, poorly differentiated lesions with a normal c-myc copy number, exhibited a median survival of 9 months. There was no apparent relationship between c-myc amplification, grade of tumor differentiation, and response to platinol-based chemotherapy. These data do not suggest a prognostic role for c-myc amplification in primary ovarian cancer. However, c-myc amplification is a common finding in advanced-stage ovarian cancer.

AB - The c-myc oncogene codes for a DNA binding protein that appears to play an important role in the regulation of cell growth. c-myc gene amplification has been documented to occur in both hematopoietic and solid neoplasms and often indicates more biologically aggressive tumors. Southern hybridization analysis was performed on high-molecular-weight DNA isolated from primary ovarian carcinomas. Major structural rearrangements of c-myc were not detected. Five of seventeen (29.4%) tumor samples demonstrated amplification of the myc oncogene. The 5 patients with ovarian carcinomas associated with c-myc amplification exhibited a median survival of 17 months. Of the 12 patients without evidence of tumor-associated c-myc amplification, 5 have exhibited disease-free survival for an average of 36.8 months and are currently alive. The remaining 7 patients, the majority of whom had advanced-stage, poorly differentiated lesions with a normal c-myc copy number, exhibited a median survival of 9 months. There was no apparent relationship between c-myc amplification, grade of tumor differentiation, and response to platinol-based chemotherapy. These data do not suggest a prognostic role for c-myc amplification in primary ovarian cancer. However, c-myc amplification is a common finding in advanced-stage ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025188561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025188561&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(90)90069-W

DO - 10.1016/0090-8258(90)90069-W

M3 - Article

C2 - 2227545

AN - SCOPUS:0025188561

VL - 38

SP - 340

EP - 342

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -